Tarsus Pharmaceuticals Reports Strong Full-Year 2025 XDEMVY Sales, Reduced Losses, and $2B+ Peak Sales Outlook

summarizeSummary

Tarsus Pharmaceuticals announced robust full-year 2025 financial results, driven by over 150% growth in XDEMVY net product sales to $451.4 million, significantly reducing its net loss and projecting over $2 billion in peak sales for the product.

check_boxKey Events

• Record XDEMVY Sales

  Full-year 2025 net product sales of XDEMVY reached $451.4 million, marking over 150% year-over-year growth, with Q4 2025 sales at $151.7 million.

• Reduced Net Loss

  The company significantly narrowed its full-year net loss to $66.4 million in 2025, down from $115.6 million in 2024, and Q4 net loss to $8.4 million from $23.1 million in the prior year.

• Strong Peak Sales Outlook

  Management projects XDEMVY's peak sales potential to exceed $2 billion, highlighting long-term commercial confidence.

• Pipeline Advancement

  Tarsus initiated a Phase 2 trial for TP-04 in ocular rosacea and plans to start a Phase 2 trial for TP-05 in Lyme disease prevention in Q2 2026.

auto_awesomeAnalysis

This 8-K details a highly positive earnings report for Tarsus Pharmaceuticals. The substantial year-over-year growth in XDEMVY sales, coupled with a significant reduction in net loss, indicates strong commercial execution and improving financial health. The company's confidence in XDEMVY's peak sales potential exceeding $2 billion provides a strong long-term growth narrative. Additionally, the advancement of its pipeline with new Phase 2 trials for ocular rosacea and Lyme disease prevention demonstrates continued investment in future growth drivers. Investors should view these results as a strong validation of the company's strategy and commercialization efforts.